Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeuroSense TherapeuticsNRSN +2.26%31 3-Year EPS without NRI Growth Rate is 21.60% as of Dec. 2025. GuruFocus rates NRSN with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 1,160 Biotechnology companies, NeuroSense Therapeutics ranks better than 56.98% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 21.60% per year.
During the past 5 years, the average EPS without NRI Growth Rate was -1.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 7 years, the highest 3-Year average EPS without NRI Growth Rate of NeuroSense Therapeutics was 21.60% per year. The lowest was -100.30% per year. And the median was -14.95% per year.
NeuroSense Therapeutics (NAS:NRSN) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
NeuroSense Therapeutics 3-Year EPS without NRI Growth Rate Related Terms
NRSN vs CELU, GRDX, ZIVO: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, NeuroSense Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeuroSense Therapeutics 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NeuroSense Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where NeuroSense Therapeutics's 3-Year EPS without NRI Growth Rate falls into.
NeuroSense Therapeutics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 21.60% mean?
NeuroSense Therapeutics (NRSN) has a 3-Year EPS without NRI Growth Rate of 21.60% as of Dec. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for NeuroSense Therapeutics and its competitors. According to the industry distribution chart, NeuroSense Therapeutics ranks #499 out of 1160 companies in the Biotechnology industry, placing it in the top 43%.
Is NeuroSense Therapeutics' 3-Year EPS without NRI Growth Rate too high?
NeuroSense Therapeutics' current 3-Year EPS without NRI Growth Rate is 21.60%. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.20. NeuroSense Therapeutics' value of 21.60% is 33.3% above this industry median. Based on the distribution chart, NeuroSense Therapeutics ranks #499 out of 1160 companies in the Biotechnology industry, which is above the industry midpoint. Overall, NeuroSense Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does NeuroSense Therapeutics' 3-Year EPS without NRI Growth Rate compare to CELU and GRDX?
According to the Biotechnology industry distribution chart, NeuroSense Therapeutics ranks #499 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This puts NeuroSense Therapeutics in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.20. NeuroSense Therapeutics' value of 21.60% is 33.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NeuroSense Therapeutics's current 3-Year EPS without NRI Growth Rate of 21.60% is 33.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for NeuroSense Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeuroSense Therapeutics's current 3-Year EPS without NRI Growth Rate is 21.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroSense Therapeutics stock overvalued right now?
NeuroSense Therapeutics (NRSN) has a current 3-Year EPS without NRI Growth Rate of 21.60%. The current 3-Year EPS without NRI Growth Rate is 21.60% and 33.3% above the Biotechnology industry median of 16.20. NeuroSense Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For NeuroSense Therapeutics (NRSN), the current 3-Year EPS without NRI Growth Rate is 21.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
31GF Score
Get the complete analysis for NRSN
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NRSN has been successfully added to your 
